Curis Schedules Shareholder Vote on Reverse Stock Split to Avoid Nasdaq Delisting
CRIS is trading near its 52-week low of $0.464 (7.6% above the low) on light trading volume (0.2× avg).
Summary
Curis Inc. has filed a definitive proxy statement scheduling a special meeting on June 25, 2026, for shareholders to vote on a reverse stock split, a measure aimed at increasing its share price to meet Nasdaq's listing requirements and prevent delisting.
Key Events · Corporate Governance and Compliance · CRIS
-
Special Shareholder Meeting Scheduled
A special meeting will be held on June 25, 2026, for stockholders to vote on a reverse stock split proposal.
-
Reverse Stock Split Proposal
The Board seeks approval for amendments to its charter to effect a reverse stock split with a ratio ranging from 1-for-5 to 1-for-25, at the Board's discretion.
-
Nasdaq Delisting Threat
The primary reason for the reverse split is to increase the stock price to meet Nasdaq's minimum $1.00 bid price requirement, following a delisting determination letter received on April 27, 2026.
-
Financial Distress Context
This proposal follows recent disclosures of 'going concern' doubt and significant net losses, highlighting the company's precarious financial position.
Analysis · CRIS · Life Sciences
This definitive proxy statement formalizes the company's plan to implement a reverse stock split, a critical step in its effort to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting. The company previously received a delisting determination letter from Nasdaq and has disclosed substantial doubt about its ability to continue as a going concern. While a reverse split does not change the company's intrinsic value, it is a necessary defensive measure to maintain its exchange listing, which is vital for liquidity and investor confidence, especially for a company in financial distress.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.6% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRIS was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $0.46 to $3.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.